Vimta Labs Limited
NSE: VIMTALABSMarket Closed • NSE
Day range
52 week range
Vimta Labs Limited closed at INR522.45 (+0.15%) on volume 0.42x its 20-day average, trading 28.92% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved +20.1% QoQ
2026-06-18
DIVIDEND Announced
Dividend - Rs 2 Per Share
2025-06-13
BONUS Announced
Bonus 1:1
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
High Cash Flow Conversion: CFO/PAT averaged 1.63x over last 3 years
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Diagnostics & Research.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 18 Jun 2026 | Dividend | ₹2.00 / share | — | 18 Jun 2026 |
| 13 Jun 2025 | Bonus issue | 1:1 bonus ratio | — | 13 Jun 2025 |
| 30 May 2025 | Dividend | ₹2.00 / share | — | 30 May 2025 |
| — | Dividend | ₹2.00 / share | — | 11 Jul 2024 |
| — | Dividend | ₹2.00 / share | — | 21 Jun 2023 |
| — | Dividend | ₹2.00 / share | — | 16 Jun 2022 |
| — | Dividend | ₹2.00 / share | — | 25 Jun 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 01 Sept 2020 |
| — | Dividend | ₹2.00 / share | — | 18 Jul 2019 |
| — | Dividend | ₹2.00 / share | — | 14 Aug 2018 |
| — | Annual General Meeting | Annual General Meeting | — | 19 Sept 2017 |
| — | Dividend | ₹1.00 / share | — | 25 Aug 2016 |
| — | Dividend | ₹1.00 / share | — | 06 Aug 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, and regulators; and a testing laboratory for water, alcoholic, and non-alcoholic beverages. In addition, the company offers environmental regulatory services, such as impact assessments and post project monitoring, to various industries, including power, infrastructure, cement, oil and gas, and mining, etc.; and EMI/EMC testing for electronic and electrical products/components. It provides solutions to agriculture, biologics and biosimilars, home and personal care, medical device, specialty chemicals, food, electrical and electronics, nutraceuticals, water and beverages, pharmaceuticals, crop care, environment, health and safety, and packaging industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India.
IndiaHealthcare
Is Vimta Labs Limited Shariah compliant?
Vimta Labs Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.14%) complies with AAOIFI threshold (≤ 33%).
What is Vimta Labs Limited's current valuation relative to peers?
Vimta Labs Limited trades at a P/E of 29.6x compared to the sector median of 37x, and a Price-to-Book of 5.1x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.73x. Interest coverage is 208.8x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at steady rates while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.